Ophthalmology billing produces denials in a small set of recurring patterns, and the same pattern typically hits every affected patient for a given payer and procedure combination. That concentration is useful: fix the root cause once and the volume drops across the board. The four patterns worth understanding are the routine-vs-medical exam distinction, post-surgical global period bundling, ancillary test bundling into the exam fee, and authorization gaps on injections and cataract surgery.
Routine vs. medical exam: the code-selection problem
The highest-volume denial pattern in ophthalmology is not a technical billing error. It's a code-selection mismatch. Eye exams have two distinct code sets: the ophthalmologic services codes (92002, 92004, 92012, 92014) and the standard evaluation and management codes (99202 through 99215). Many commercial plans route the 92000-series codes to vision benefits, while E/M codes go to medical benefits. Routing a diabetes-related retinal exam to a vision plan produces a denial because vision benefits typically exclude medical conditions; routing it to the medical benefit with a 92014 code may also deny if the plan requires E/M codes for medical visits.
The fix requires knowing, per payer, which code set applies to which clinical situation and which benefit bucket they draw from. A patient presenting solely for a glasses prescription gets a vision exam code billed to vision benefits. A patient presenting for monitoring of diabetic macular edema gets either the appropriate ophthalmologic code or an E/M, billed to medical benefits, depending on the payer's rules. Mixing these up generates denials that look like coverage problems but are actually code-routing problems, and a corrected claim with the right code and the right benefit specified usually resolves them.
CO-97 and the cataract global period
Cataract extraction carries a 90-day global period. The surgical fee includes all routine post-op visits during that 90 days, so a follow-up visit billed separately without the right modifier produces a CO-97 bundling denial. Three modifiers exist for circumstances where a separate bill is appropriate: modifier 24 for an evaluation and management service completely unrelated to the surgery (a patient who develops an unrelated condition during the global period), modifier 79 for a separately identifiable procedure unrelated to the original surgery, and modifier 78 for a return to the operating room for a related complication.
When CO-97 denials cluster around a specific time window after cataract surgery, it is worth reviewing whether the visit notes document a separately identifiable condition. A visit note that reads only as routine post-op follow-up will not support a modifier 24 appeal. A note documenting a new, unrelated finding (elevated IOP, a corneal issue, a systemic complaint) can support a separate bill when the documentation is explicit about the distinction.
Ancillary test bundling: OCT, visual fields, and fundus photos
Optical coherence tomography (92134), visual field testing (92083), and fundus photography (92250) are separately billable when each has a distinct clinical indication documented in the note. Payers vary on whether they price these independently or bundle them into the comprehensive exam fee. Before appealing a bundling denial on any of these, check the payer's own allowable list: if the payer's fee schedule does not separately price the code, the bundling is consistent with the contract and the dispute will not succeed.
For payers that do separately price these codes, CO-50 medical necessity denials on OCT and visual fields are common. The appeal needs the specific clinical indication documented in the note: the diagnosis (glaucoma, diabetic macular edema, age-related macular degeneration, suspected papilledema), how long the condition has been present or monitored, and the explicit clinical reason the test was ordered at this visit rather than deferred. A generic "monitoring AMD" note loses CO-50 appeals more often than a note that documents the specific finding prompting the test.
Authorization gaps for injections and surgery
Intravitreal injections (CPT 67028) for anti-VEGF therapy represent some of the highest-dollar claims in ophthalmology, and they typically require two separate authorizations: one for the procedure and one for the drug. The J-code for the drug (J0178 for aflibercept, J2781 for ranibizumab, J9035 for bevacizumab, J2181 for faricimab) must be authorized independently from the injection procedure. A practice that obtains auth for the office visit and the procedure but not the drug J-code will see the drug line deny as CO-197 on every injection claim until the drug authorization is obtained and attached.
Cataract surgery has similar two-track authorization requirements at many payers: one authorization for the surgical procedure and a separate authorization for any premium intraocular lens (IOL) upgrade when the patient selects a multifocal or toric lens. Standard monofocal IOLs are typically included in the surgery auth; premium lenses often require explicit coverage verification and, in some cases, a separate benefit determination.
Addressing these patterns upstream
Because ophthalmology denial patterns repeat by payer and procedure, a small amount of systematic work at the front end prevents large denial volumes downstream. Maintain a payer-specific reference for the routine-vs-medical code routing decision, verify authorization for both the procedure and any separately authorized drug or device before each injection or surgical date, and audit CO-97 denials by date-of-service relative to prior surgical dates to catch global-period misses early. The patterns described here are ones where a systemic fix stops the recurring loss rather than working each claim individually. That is where the revenue leakage approach makes the most difference.